Impact of Metabolic Associated Steatotic Liver Disease on Antiviral Therapy Outcomes on Chronic Hepatitis B Patients Receiving Antiviral Therapy

抗病毒治疗 医学 抗病毒治疗 免疫学 病毒学 免疫系统 炎症 慢性肝炎 纤维化 病毒 病毒性疾病 脂肪变性 疾病 病毒载量 肝病 抗病毒药物 内科学 病毒性肝炎 乙型肝炎病毒 免疫调节 乙型肝炎 丙型肝炎病毒 丙型肝炎 免疫状态 药物治疗 联合疗法 慢性肝病 肝纤维化 脂质代谢 肝炎 黄病毒科 干扰素
作者
Sheng‐Jie Shiue,Tung‐Han Ho,Hsin‐Yi Lin,Sheng‐Wei Cheng,Li‐Wei Wu,Tze‐Sian Chan,Chun‐Nan Chen,Chao-Ling Cheng,Yan Kang Lee,Hsien‐Yao Yang,Han-Shiang Shiue,Kuo-Feng Leng,Ming‐Shun Wu
出处
期刊:Journal of Medical Virology [Wiley]
卷期号:98 (3): e70864-e70864 被引量:5
标识
DOI:10.1002/jmv.70864
摘要

BACKGROUND AND AIM: Chronic hepatitis B (CHB) affects over 250 million people globally and is a major contributor to liver complications, including cirrhosis and hepatocellular carcinoma (HCC). Though antiviral therapies suppress HBV, the rising prevalence of metabolic-associated steatotic liver disease (MASLD) poses new challenges. This study assessed how MASLD influences liver-related outcomes, fibrosis progression, and survival in CHB patients undergoing nucleus(t)ide analogs (NAs) therapy, using large-scale data and clinical cohort analysis. METHODS: A retrospective study using the TriNetX US Collaborative Network, CHB patients receiving long-term NA therapy with undetectable serum HBV DNA and concomitant MASLD (CHB-MASLD-NA, n = 5600) were compared with those without MASLD (CHB-non MASLD-NA, n = 11 021), matched 1:1 by propensity scores (n = 4761 each after matching). Primary outcomes included 10-year incidence of HCC and cirrhosis, with survival assessed via Kaplan-Meier curves and hazard ratios (HRs) from Cox models. Separately, a clinical cohort of 64 CHB patients and 137 MASLD-only patients was assessed for steatosis (controlled attenuation parameter, CAP) and fibrosis (liver stiffness). RESULTS: Analysis revealed that co-existing MASLD significantly compromised clinical outcomes. CHB-MASLD-NA patients faced a substantially higher risk of developing cirrhosis or HCC (HR 1.75, 95% CI 1.53-2.00, p < 0.001) and demonstrated lower 10-year survival rates (61.5% vs. 79.3%, p < 0.001) compared to the non-MASLD group. These findings were corroborated by the clinical cohort, where CHB-MASLD-NA patients exhibited greater liver stiffness (9.85 vs. 4.95 kPa) and a higher prevalence of advanced fibrosis compared to CHB alone and MASLD-only groups (28.0% vs. 14.3% and 4.4%). HBV DNA load was not a significant predictor of outcomes in this population (HR 1.00). Notably, as steatosis worsened, the pro-inflammatory cytokine TNF-α increased more sharply (3.73-fold) than the antiviral cytokine IFN-γ (2.13-fold). CONCLUSIONS: MASLD drives fibrosis and mortality in NA-treated CHB patients, as metabolic inflammation overrides the benefits of viral suppression. Integrated management, combining antiviral therapy, metabolic intervention, and immune monitoring, is essential to accurately assess progression and improve long-term prognosis.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
搜集达人的应助被AoAoo采纳,获得10
2秒前
easynature完成签到 ,获得积分20
2秒前
372721759发布了新的文献求助30
2秒前
cdercder的应助被TinTin采纳,获得10
3秒前
风趣小松鼠完成签到,获得积分10
3秒前
科研通AI2S的应助被Lu采纳,获得10
3秒前
Plus是只喵完成签到,获得积分20
3秒前
3秒前
4秒前
洁净盛男发布了新的文献求助30
5秒前
所所的应助被奇异果采纳,获得10
5秒前
6秒前
怕黑的飞柏完成签到 ,获得积分10
6秒前
lllllll完成签到 ,获得积分10
7秒前
7秒前
田様的应助被ynuxb采纳,获得10
7秒前
7秒前
aaa关闭了aaa的文献求助
8秒前
新新完成签到 ,获得积分20
8秒前
Nichols完成签到,获得积分0
8秒前
wty完成签到,获得积分10
8秒前
辛未发布了新的文献求助10
9秒前
科研通AI6.4的应助被TINASO采纳,获得10
9秒前
9秒前
小川完成签到,获得积分10
9秒前
张y发布了新的文献求助10
10秒前
10秒前
10秒前
Zhangyuanjie发布了新的文献求助10
11秒前
安安发布了新的文献求助30
11秒前
11秒前
12秒前
喵喵轩完成签到,获得积分10
12秒前
13秒前
n11发布了新的文献求助10
13秒前
威武的海棠花完成签到,获得积分10
13秒前
13秒前
14秒前
juju发布了新的文献求助10
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183204
求助须知:如何正确求助?哪些是违规求助? 9572482
关于积分的说明 21825940
捐赠科研通 7780074
什么是DOI,文献DOI怎么找? 3433945
关于科研通互助平台的介绍 2558060
邀请新用户注册赠送积分活动 2480166